Loading...
An investigational soluble formulation of levodopa and carbidopa prodrugs, known as foslevodopa-foscarbidopa, has been suggested as a continuous subcutaneous infusion therapy for patients with advanced Parkinson disease (PD). To assess the safety and efficacy of this approach, investigators in the U.S. and Australia have conducted an industry-funded, multicenter, randomized, double-blind, double-dummy, active-controlled, phase 3 study in which 141 advanced PD patients (with an average daily “off” time of ≥2.5 hours) were assigned to receive continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo or continuous subcutaneous infusion of placebo plus oral levodopa-carbidopa.
After 12 weeks of treatment, patients who receiv…